Free Trial
NASDAQ:KYTX

Kyverna Therapeutics Q1 2025 Earnings Report

Kyverna Therapeutics logo
$2.11 -0.02 (-0.94%)
As of 05/9/2025 04:00 PM Eastern

Kyverna Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$1.21
Beat/Miss
N/A
One Year Ago EPS
N/A

Kyverna Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kyverna Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Kyverna Therapeutics Earnings Headlines

Contrasting Kyverna Therapeutics (KYTX) & Its Rivals
One Stock Gold Blueprint to Survive the Market Chaos
One Stock Gold Blueprint to Survive the Market Chaos Markets are volatile, uncertainty is everywhere, and Americans are trying to protect their wealth. Fortunately, millionaire trader Jeff Clark has revealed a powerful strategy built for times like these — one that doesn't rely on predicting the market. Rather, Jeff's strategy takes advantage of the chaos to uncover potential gains. It all centers around one single stock designed to prosper whenever gold moves, no matter the direction.
Kyverna Therapeutics price target lowered to $12 from $13 at UBS
See More Kyverna Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kyverna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kyverna Therapeutics and other key companies, straight to your email.

About Kyverna Therapeutics

Kyverna Therapeutics (NASDAQ:KYTX), a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

View Kyverna Therapeutics Profile

More Earnings Resources from MarketBeat